We were the first group to demonstrate that the increased expression of METCAM in a human prostate cancer cell line, LNCaP, enhances its EMT (epithelial-to-mesenchymal transition) activity, as shown in analyses of augmented motility and invasiveness. The gene discussed is MCAM; the disease is prostate carcinoma.